Does CAPMATINIB Cause Non-small cell lung cancer? 96 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 96 reports of Non-small cell lung cancer have been filed in association with CAPMATINIB (TABRECTA). This represents 4.2% of all adverse event reports for CAPMATINIB.
96
Reports of Non-small cell lung cancer with CAPMATINIB
4.2%
of all CAPMATINIB reports
37
Deaths
21
Hospitalizations
How Dangerous Is Non-small cell lung cancer From CAPMATINIB?
Of the 96 reports, 37 (38.5%) resulted in death, 21 (21.9%) required hospitalization, and 6 (6.3%) were considered life-threatening.
Is Non-small cell lung cancer Listed in the Official Label?
Yes, Non-small cell lung cancer is listed as a known adverse reaction in the official FDA drug label for CAPMATINIB.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Malignant neoplasm progression (178)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Decreased appetite (95)
What Other Drugs Cause Non-small cell lung cancer?
SOTORASIB (483)
CARBOPLATIN (431)
BRIGATINIB (370)
NIVOLUMAB (366)
PACLITAXEL (275)
IPILIMUMAB (273)
PEMETREXED (234)
CERITINIB (183)
CRIZOTINIB (178)
AMG-510 (134)
Which CAPMATINIB Alternatives Have Lower Non-small cell lung cancer Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN